A study on KPV was published on August 9, 2026, in the journal Tissue & Cell. The publication is titled "KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling." KPV remains classified as an unapproved compound used only in research settings. The publication record, indexed under PubMed ID 42585803, documents the title and journal placement of this new work. This brief reports only the existence and title of the publication as listed in the source record. No specific findings, data, or outcomes from the study are described here beyond the title itself. Readers interested in the full scope of the research should consult the original publication directly through the linked source. As with all research-stage compounds, KPV has not been evaluated by regulatory authorities for safety or effectiveness in humans. The appearance of a new publication reflects ongoing academic interest in the compound but does not itself indicate any conclusion about its properties. For more background on KPV, readers can refer to the compound overview.
New KPV Publication in Tissue & Cell Examines Lipid Signaling
Source: https://pubmed.ncbi.nlm.nih.gov/42585803/